DR. ZAID S ARDALAN (Orcid ID : 0000-0001-6952-0985)

Article type : Original Articles

Management of patients with EPP related progressive liver disease

Ardalan, ZS^{1,2}; Chandran, S¹; Vasudevan A³; Angus, P^{1,4}; Grigg, A⁵; He S⁵; Macdonald, GA⁶; Strasser, SI^{7,8}; Tate, CJ^{9,10}; Kennedy, GA^{9,10}; Testro, A¹; Gow, PJ¹

1 Department of Gastroenterology and Liver Transplant, Austin Hospital, Melbourne, Australia

2 Department of Gastroenterology, The Alfred Hospital, Melbourne, Australia

3 Department of Gastroenterology, Eastern Health, Melbourne Australia

4 Melbourne University, Melbourne, Australia

5 Department of Clinical Hematology Austin Hospital, Melbourne, Australia

6 Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Australia

7 AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia

8 University of Sydney, Sydney, Australia

9 Department of Department of Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia

10 University of Queensland, Brisbane, Australia

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as [doi: 10.1002/LT.25632](https://doi.org/10.1002/LT.25632)

This article is protected by copyright. All rights reserved

Zaid S Ardalan

Postal Address: Department of Gastroenterology

The Alfred Hospital, 55 Commercial Rd, Melbourne VIC 3004

Email: zaid.ardalan@gmail.com

First and corresponding author

Sujievvan Chandran

Postal Address: Department of Gastroenterology and Liver Transplantation,

Austin Hospital, 145 Studley Road, Heidelberg, Victoria, Australia, 3084

sujievvan@me.com

Involved in drafting the manuscript. Registrar involved in patient care in Victoria.

Abhinav Vasudevan

Postal Address: Department of Gastroenterology

Eastern Health, 5 Arnold St, Box Hill VIC 3128

Email: abhinav.vasudevan@gmail.com

Assisted in drafting the manuscript

Peter W Angus

Postal Address: Department of Gastroenterology and Liver Transplantation,

Austin Hospital, 145 Studley Road, Heidelberg, Victoria, Australia, 3084

Email: peter.angus@austin.org.au

Critical review. Supervised in drafting the manuscript.

Andrew Grigg

Postal Address: Department of Clinical Hematology

Austin Hospital, 145 Studley Road, Heidelberg, Victoria, Australia.

Andrew.grigg@austin.org.au

Haematologist involved in patients' care. Significant contribution to the revision of the manuscript.

This article is protected by copyright. All rights reserved

Simon He

Postal Address: Department of Clinical Hematology

Austin Hospital, 145 Studley Road, Heidelberg, Victoria, Australia.

Simon.He@austin.org.au

Hematologist involved in patients' care. Revision of the manuscript

Graeme Macdonald

Department of Gastroenterology and Hepatology

Princess Alexandra Hospital, Brisbane, Australia

Graeme_Macdonald@health.qld.gov.au

Physician involved in patients' care. Data collection

Simon I Strasser

Postal address: AW Morrow Gastroenterology and Liver Centre,

Royal Prince Alfred Hospital, Sydney, Australia.

Simone.Strasser@health.nsw.gov.au

Physician involved in patients' care. Data collection.

Courtney J Tate

Post address

Department of Department of Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia Herston QLD 4029

courtmodra@hotmail.com

Physician involved in patients' care. Data collection.

Glen A Kennedy

Post address: Department of Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia Herston QLD 4029

Glen.kennedy@health.qld.gov.au

Physician involved in patients' care. Data collection.

Adam G Testro

Postal Address: Department of Gastroenterology and Liver Transplantation,
Austin Hospital, 145 Studley Road, Heidelberg, Victoria, Australia, 3084

Adam.testro@austin.org.au

Supervised writing the manuscript.

Paul J Gow

Postal Address: Department of Gastroenterology and Liver Transplantation,
Austin Hospital, 145 Studley Road, Heidelberg, Victoria, Australia, 3084

paul.gow@austin.org.au

Supervising Author

Kew words

1. Protoporphyrin IX
2. XLP
3. Red cell exchange
4. Liver transplantation
5. Allogeneic stem cell transplant

Footnote page

Abbreviation	Definition

ALAS2	5-aminolevulinic acid synthase 2
AlloSCT	Allogeneic stem cell transplantation
ALP	Alkaline phosphatase
AST	Aspartate aminotransferase
EPP	Erythropoietic protoporphyria
Erc-PPIX	Erythrocyte protoporphyrin
FECH	Ferrochelatase
GVHD	Graft versus host disease
Hb	Hemoglobin
IDA	Iron deficiency anemia
INR	International normalised ratio
LFT	Liver function test
MELD	Model for End Stage Liver Disease
MUD	Matched unrelated donor
OLT	Orthotopic liver transplant
P-PPIX	Plasma Protoporphyrin
PBSCT	Peripheral blood stem cell transplant
PPIX	Protoporphyrin IX
RBC	Red blood cell
RBCs	Red blood cells
RCE	Red cell exchange
XLP	X-Linked EPP

There were no grants or financial support involved in this research.

None of the Authors have any conflict of interest to declare.

Zaid S Ardalan is the *guarantor*.

- Email zaid.ardalan@gmail.com
- Phone number 0061409730301
- Postal Address: Department of Gastroenterology, The Alfred Hospital,
55 Commercial Rd, Melbourne VIC, Australia 3004

Abstract

Erythropoietic protoporphyria (EPP) is an inherited metabolic disorder of heme synthesis resulting from overproduction of protoporphyrin IX (PPIX) which can lead to progressive liver disease characterized by recurrent EPP crisis and end stage liver disease. We utilized the Australian Transplant Registry to identify five patients referred for liver transplantation between 2008 and 2017. Four patients had EPP secondary to ferrochelatase (FECH) deficiency and one had X-Linked EPP (XLP). No patient had specialist follow-up prior to the diagnosis of progressive liver disease. Three patients underwent orthotopic liver transplant (OLT), while two died while on the transplant waiting list. Parenteral PPIX-lowering therapy was utilized in four patients and was effective in three patients although two of these had rebound porphyria and worsening liver function following decreasing the intensity of therapy. Early disease recurrence in the allograft following transplantation occurred in two patients requiring red cell exchange (RCE) to successfully attain and maintain low PPIX levels, but RCE was associated with hemosiderosis in one case. Allogeneic stem cell transplantation (AlloSCT) was performed in two patients. One failed engraftment twice while the second rejected their first graft but achieved full donor chimerism with a second graft and increased immunosuppression. Conclusion: Our observations suggest that progressive liver disease needs parenteral PPIX-lowering treatment with

the intensity adjusted to achieve a target Erc-PPIX level. Since recurrent EPP liver disease is the rule, AlloSCT should be considered in all patients with adequate immunosuppression to facilitate engraftment. RCE appears effective for recurrent EPP liver disease but is associated with an increased risk of iron overload.

Introduction

Erythropoietic protoporphyria (EPP) is an inherited metabolic disorder of heme synthesis resulting in overproduction of protoporphyrin IX (PPIX) which accumulates in erythrocytes, skin and liver. It is most commonly an autosomal recessive disorder, characterized by reduced production of ferrochelatase (FECH), required to convert protoporphyrin to heme.(1, 2) Less commonly, EPP may result from an X-linked gain of function mutation in the 5-aminolevulinic acid synthase 2 (ALAS2) gene, required for the synthesis of 5-ALA, the rate limiting enzyme in heme synthesis;(3) this is known as X-Linked Protoporphyria(XLP).

Excess PPIX production occurs primarily in the bone marrow and diffuses across red blood cell (RBC) membranes into the plasma, where it is albumin bound and taken up by the liver for secretion into bile. Liver damage, characterised by cholestasis, inflammation, fibrosis and cirrhosis,(4) has been attributed to precipitation of toxic insoluble PPIX in bile canaliculi and to protoporphyrin-induced oxidative damage to hepatic membrane-bound enzymes.(1, 5)

Progressive liver disease manifests in only 1-5% of patients with EPP and impaired hepatobiliary clearance can result in further increases in erythrocyte protoporphyrin (Erc-PPIX) leading to rapid progression of liver disease.(6) Rising Erc-PPIX levels can also precipitate EPP crises in patients with pre-existing liver disease, characterized by acute deterioration in liver function, severe abdominal pain, jaundice, and worsening photosensitivity.(7)

Various treatment strategies are used for the management of EPP related liver disease, although evidence for their efficacy is limited. (10-13). (Table 1)

Orthotopic liver transplantation (OLT) is the only effective treatment for EPP-related end stage liver disease.(6, 8, 9) However, OLT does not correct

defective heme synthesis, so disease recurrence in the allograft is common and ongoing PPIX-lowering therapy is required in the post-transplant setting. The only definitive cure for EPP remains an AlloSCT to correct the defect in heme synthesis.(8, 10)

We report five cases of EPP-related progressive liver disease referred for OLT in Australia between 2008-2017.

METHODS AND RESULTS

Five patients referred with EPP-related progressive liver disease for OLT between the years 2008 and 2017 were identified using the Australian Liver Transplant Registry which reported 2276 liver transplants over this time period. Tables 2 and 3 summarise the key features of the five cases.

CASE 1

A 41-year-old female was referred for OLT with EPP-crisis. EPP, secondary to FECH deficiency, was diagnosed at the age of 22 years and managed with strict sun avoidance and beta-carotene. Liver biopsy three years prior to referral confirmed EPP-related liver disease with minimal periportal fibrosis.

EPP crisis manifested with jaundice, abdominal pain and vomiting with an aspartate aminotransferase (AST) 248 IU/L (reference range <31 IU/L), an alkaline phosphatase (ALP) of 167 IU/L (reference range 30-120 IU/L), a bilirubin of 68 $\mu\text{mol/L}$ (reference range 0-20 $\mu\text{mol/L}$) and an international normalised ratio (INR) of 1.2. Erc-PPIX was 149 $\mu\text{mol/L}$ (8371 $\mu\text{g/dL}$) (reference range <1.8 $\mu\text{mol/L}$; <101 $\mu\text{g/dL}$). Liver biopsy confirmed cirrhosis with abundant protoporphyrin pigment consistent with EPP-related cirrhosis. PPIX-lowering treatment was instituted with daily infusions of heme arginate 3mg/kg for three days and 500 mg of ursodeoxycholic acid twice daily. Whilst symptoms resolved and bilirubin decreased to 38 $\mu\text{mol/L}$ there was no change in Erc-PPIX.

Two weeks later there was a recurrence of EPP crisis in the setting of an elevated Erc-PPIX of 331 $\mu\text{mol/L}$ (18596 $\mu\text{g/dL}$). PPIX-lowering treatments were reinstituted with heme arginate, plasma exchange and RBC hypertransfusions (Hemoglobin (Hb) target of ≥ 120 g/L). The Erc-PPIX

reduced to 120 $\mu\text{mol/L}$ by week 4 of admission and plasma exchange was performed weekly thereafter. A month later, she developed progressive neuropathy in the context of rising Erc-PPIX (401 $\mu\text{mol/L}$ or 22528 $\mu\text{g/dL}$) and a dropping Hb (90 g/L). Daily plasma exchange and heme arginate were recommenced. Despite Erc-PPIX levels falling to 105 $\mu\text{mol/L}$ (5899 $\mu\text{g/dL}$), neuropathy worsened and she developed type 2 respiratory failure and hepatorenal syndrome leading to death.

Case 2

A 20-year-old female was referred for OLT with complications of end stage liver disease. EPP, secondary to FECH deficiency, was diagnosed at the age of four years and managed with strict sun avoidance and beta-carotene. Liver involvement was noted two years prior to referral on liver biopsy with features of cholestasis and bridging fibrosis for which cholestyramine was commenced. She was admitted with decompensated cirrhosis with a Model for End Stage Liver Disease (MELD) score of 24 and an Erc-PPIX of 172 $\mu\text{mol/L}$ (9663 $\mu\text{g/dL}$). Heme arginate 3mg/kg four days per week for two weeks failed to produce clinical improvement despite a falling Erc-PPIX level to 105 $\mu\text{mol/L}$ (5899 $\mu\text{g/dL}$). While on the transplant waiting list, she developed multi-organ failure and sepsis leading to her death.

Case 3

A 25-year-old female was referred to the liver transplant and hematology units for consideration of sequential OLT and AlloSCT for EPP-related end stage liver disease. X-Linked Protoporphyrria (XLP) was diagnosed at the age of 18 months and managed with strict sun avoidance and beta-carotene. At the age of 15 years she developed recurrent episodes of EPP crisis. A year later, decompensated cirrhosis due to XLP was confirmed on liver biopsy. At the time Erc-PPIX was 180 $\mu\text{mol/L}$ (10112 $\mu\text{g/dL}$) and she had iron deficiency anemia (IDA) with a Hb of 95 g/L and a serum ferritin of 13 $\mu\text{g/L}$. PPIX-lowering treatment included 7 days of IV hematin (3mg/kg), ursodeoxycholic acid 250 mg three times daily (12mg/kg/d) and oral iron replacement. OLT was considered, but refused by the patient. Liver function tests (LFTs) remained normal for 2.5 years on this treatment and the mean Erc-PPIX was

19.7 $\mu\text{mol/L}$ (1107 $\mu\text{g/dL}$). At the age of 20, splenic embolization was performed for hypersplenism associated with severe neutropenia, recurrent infections and thrombocytopenia. For the following 5 years she remained stable with a mean Erc-PPIX of 11 $\mu\text{mol/L}$ (618 $\mu\text{g/dL}$) on ursodeoxycholic acid.

At the age of 25, she developed end stage liver disease. Erc-PPIX was 210 $\mu\text{mol/L}$ (11798 $\mu\text{g/dL}$) with concomitant IDA. She was worked up for sequential OLT and AlloSCT. While awaiting liver transplantation she had two admissions for EPP crisis in the setting of rising Erc-PPIX with a mean of 74 $\mu\text{mol/L}$ (4157 $\mu\text{g/dL}$) and iron deficiency. Both crises were managed with hematin and plasmapheresis. The second crisis was followed by eight infusions of iron fortnightly, and subsequently daily 15ml of liquid iron (30 mg/ml) until OLT four months later when Erc-PPIX was 16 $\mu\text{mol/L}$ (899 $\mu\text{g/dL}$). (Figure 1).

OLT was performed with the use of light filters omitting wavelength $<420\text{nm}$. The explant showed cirrhosis with birefringent protoporphyrin pigment and moderate hepatocyte iron accumulation (grade 2 siderosis). The early post-transplant course was complicated by acute cellular rejection and an anastomotic biliary stricture requiring stenting. On day 20, a liver biopsy performed for ongoing derangement in LFTs and rising Erc-PPIX (55 $\mu\text{mol/L}$ or 3090 $\mu\text{g/dL}$), demonstrated recurrent EPP liver disease, despite being on ursodeoxycholic acid 750mg bd and cholestyramine 4gm twice daily post-operatively. This failed to respond to five days of hematin, intravenous iron, RBC hypertransfusion and a total of 13 sessions of plasma exchange over 3 weeks, but responded rapidly to red cell exchange, initially twice weekly then weekly for nearly 7 months successfully attaining and maintaining Erc-PPIX of $<5 \mu\text{mol/L}$ ($<280 \mu\text{g/dL}$). Subsequently, the frequency of red cell exchange was reduced to monthly.

Two AlloSCTs from unrelated donors were performed. The first occurred four months post-OLT using marrow from a 38-year-old, nulliparous female, 10/10 HLA-matched unrelated donor (MUD). Conditioning was with cyclophosphamide (50mg/kg/day -5 to -2) and anti-thymocyte globulin 30mg/kg/day (days -5 to -3). Graft versus host disease (GVHD) prophylaxis

was with tacrolimus and mycophenolate. Engraftment failure was documented by day 22 and 28 chimerism studies of 10% and 0% donor total mononuclear cells, respectively. A second AlloSCT was performed 4 months later using a different donor; a 44-year-old male, 10/10-HLA matched MUD, with no donor HLA antibodies and with more immunosuppressive conditioning regimen consisting of fludarabine 25mg/m²/day (day -6 to -2), cyclophosphamide 500mg/m²/day (day -6 to -3), Alemtuzumab 20 mg/day (Days -5 to -1), and similar GVHD prophylaxis. Despite these measures the donor failed to engraft.

Eight years post OLT, the patient remains on ursodeoxycholic acid 750mg bd, cholestyramine 4gm bd and regular red cell exchange every 4-5 weeks with a mean Erc-PPIX of 5 µmol/L (280µg/dL), normal LFTs, a mean serum ferritin of 312 µg/L and transferrin saturation of 35% without any iron chelating agents.

CASE 4

A 21-year-old female was referred for OLT with EPP crisis. She was diagnosed with EPP, secondary to FECH deficiency, at the age of 2 years managed with strict sun avoidance. Blood test two years prior to referral, showed normal liver function but an Erc-PPIX of 64 µmol/L (3596 µg/dL). A liver biopsy confirmed EPP-related cirrhosis with severe cholestasis and protoporphyrin pigment. MELD score was 20, Erc-PPIX was 157µmol/L (8820 µg/dL) and Hb was 95 g/L with a serum ferritin of 14 µg/L. PPIX-lowering therapy was commenced, consisting of cholestyramine 8 gm twice daily, ursodeoxycholic 15 mg/kg/day, RBC hypertransfusion, 3mg/kg/d of heme arginate infusion and four days of daily plasmapheresis, reducing the Erc-PPIX to 87 µmol/L (4888 µg/dL). In the setting of line-related sepsis, no further parenteral PPIX-lowering treatment was given. She was readmitted six weeks later with EPP crisis with an Erc-PPIX of 142 µmol/L (7978 µg/dL). PPIX-lowering therapy was re-instituted with heme arginate, plasma exchange and RBC hypertransfusion. This resulted in reduction of Erc-PPIX to 42 µmol/L (2360 µg/dL). Upon discharge, heme arginate and plasma exchange were maintained at once a week up until OLT two months later when Erc-PPIX was 101 µmol/L (5674 µg/dL). (Figure 2)

At liver transplantation, yellow filters, omitting wavelengths <470 nm, were placed in theatre. A single plasma exchange was performed on day 3. She was discharged with an Erc-PPIX of 59 $\mu\text{mol/L}$ (3314 $\mu\text{g/dL}$) on ursodeoxycholic acid 500 mg twice daily and ferrous sulphate (105 mg of elemental iron) daily. Cotrimoxazole (160/800 mg) three times a week was used for pneumocystis jiroveci pneumonia (PJP) prophylaxis for 6 months. A biliary anastomotic stricture was diagnosed, dilated and stented at day 39 post-OLT. On day 60 post-OLT, a liver biopsy, performed for abnormal LFTs and a rising Erc-PPIX (118 $\mu\text{mol/L}$ or 6629 $\mu\text{g/dL}$), confirmed recurrent EPP liver disease. Reinstitution of plasma exchange and heme arginate was ineffective. Consequently, plasma exchange was replaced with weekly red cell exchange, using erythrocytapheresis. This involved removing 6 units of red blood cells (RBCs) from the patient and transfusing equivalent units of matched RBCs. This successfully reduced Erc-PPIX to 36 $\mu\text{mol/L}$ (2023 $\mu\text{g/dL}$) over 6 weeks. Red cell exchange was gradually reduced to third weekly maintaining a mean Erc-PPIX of 79 $\mu\text{mol/L}$ (4438 $\mu\text{g/dL}$). Approximately 1 year after EPP recurrence, a liver biopsy revealed cirrhosis with minimal protoporphyrin pigment and significant hepatocyte iron accumulation (grade 3 siderosis); serum ferritin was 1600 $\mu\text{g/L}$ with transferrin saturation of 86%. Haemochromatosis gene testing showed heterozygosity for the C282Y mutation. Ferrous sulphate was stopped and iron chelation with deferasirox commenced at a dose of 500 mg daily (7.5mg/kg/day) but discontinued a month later due to intolerance. Third weekly red cell exchange for four years maintained a mean Erc-PPIX of 63 $\mu\text{mol/L}$ (3539 $\mu\text{g/dL}$), a mean ALT of 45 IU/L, and a normal bilirubin. Despite this, decompensated cirrhosis developed. A repeat liver biopsy 15 months post-OLT showed cirrhosis with minimal protoporphyrin pigment and grade 4 hemosiderosis with deposition of hemosiderin in hepatocytes, portal stroma and bile duct epithelium. The mean serum ferritin over the preceding 4 years was 2174 $\mu\text{g/L}$ and mean transferrin saturation was 90%. Deferasirox was recommenced at a small tolerated dose of 125 mg bd and the patient was worked up for sequential OLT and a peripheral blood stem cell transplant (PBSCT). (Figure 3)

Due to massive splenomegaly, a splenectomy was performed at the time of second OLT with the intention to improve stem cell engraftment. While awaiting PBSCT, PPIX-lowering measures included cholestyramine, ursodeoxycholic acid and red cell exchange (thrice weekly initially then twice weekly) along with 20mg/kg/d of deferasirox, maintaining Erc-PPIX levels around 25 $\mu\text{mol/L}$ (1405 $\mu\text{g/dL}$). Pentamidine was used instead of cotrimoxazole for PJP prophylaxis. The first PBSCT, five months post-OLT, was from a 29-year-old female HLA-MUD, matched at HLA-A, B, C, -DRB1, DRB4/5 and DQB1 and mismatched at 2 HLA-DPB1 alleles. Conditioning regimen was fludarabine 25mg/m² for 5 days, cyclophosphamide (60mg/kg for 2 days)) and thymoglobulin (4.5mg/kg in total over 3 days), and GVHD prophylaxis with cyclosporine and methotrexate (day 1,3,6 and 11). It resulted in partial donor chimerism (donor CD3 <30%) with eventual graft loss by day 100, concomitant with a mild rise in Erc-PPIX to a mean of 33 $\mu\text{mol/L}$ (1854 $\mu\text{g/dL}$). The allograft was complicated at day 56 by an EBV-positive posttransplant lymphoproliferative disease presenting with a transverse myelitis-like sensory neuropathy and intensely PET avid tonsillar, cervical and paratracheal nodes with EBV DNA viremia (peaking at 2645 copies/ml of plasma). This responded to a single 375mg/m² dose of rituximab and withdrawal of immunosuppression with resolution of viremia, lymphadenopathy and steady improvement of sensory neuropathy.

A second PBSCT was performed six months after the first, with an unchanged fludarabine schedule but replacement of cyclophosphamide with melphalan 100mg/m² followed by infusion of cryopreserved peripheral blood stem cells from original donor. The increased conditioning intensity and omission of T-cell depletion were due to previous concerns of early graft rejection.(11, 12) Successful donor chimerism were confirmed at day 20+ and maintained at 1year post second allograft without active GVHD while on immunosuppression regimen of tacrolimus and mycophenolate substituting for cyclosporine due to intolerance. Normal Erc-PPIX of 0.6 $\mu\text{mol/L}$ (34 $\mu\text{g/dL}$) was also achieved at day 20+ post second allograft and maintained, off all invasive PPIX-lowering measures, at the latest follow-up at 1 year, with only

minimally abnormal LFTs without any veno-occlusive disease and able to tolerate sunlight without cutaneous photosensitivity.

CASE 5

A 64-year-old man with EPP, secondary to FECH deficiency; diagnosed at the age of 39 years and managed with strict sun avoidance, was referred for OLT with a 1-year history of end stage liver disease. This occurred on a background of known EPP-related cirrhosis diagnosed 12 years previously on no PPIX-lowering treatment.

At the time of the referral, he had a MELD of 23 with a bilirubin of 467 $\mu\text{mol/L}$, and an Erc-PPIX of 210 $\mu\text{mol/L}$ (11798 $\mu\text{g/dL}$). He was considered for liver transplantation but spontaneously recovered with normalisation of his bilirubin and INR. Six months later, he developed worsening ascites and jaundice with a bilirubin of 530 $\mu\text{mol/L}$, an INR of 1.8 and creatinine of 140 $\mu\text{mol/L}$ yielding a MELD of 30. This developed five days following an iron infusion for IDA with a Hb of 117g/L, and a serum ferritin of 11 $\mu\text{g/L}$. Erc-PPIX was 100 $\mu\text{mol/L}$ (5618 $\mu\text{g/dL}$). He was worked up for OLT and responded to supportive measures but no PPIX-lowering treatment was initiated until OLT three weeks later at which time his Erc-PPIX was 150 $\mu\text{mol/L}$ (8427 $\mu\text{g/dL}$). At transplantation flexible yellow filters, omitting wavelengths <470 nm, were placed in theatre, and plasma exchange was performed perioperatively. Explant liver had features consistent with EPP-cirrhosis, severe cholestasis and grade I siderosis, with iron deposits in the hepatocytes.

Post OLT, plasma exchange was performed day 1 and 3, and heme arginate at a dose of 3mg/kg was infused daily for 4 days. Erc-PPIX was 75 $\mu\text{mol/L}$ (4214 $\mu\text{g/dL}$) upon discharge 3 weeks later. Subsequently, cholestyramine and ursodeoxycholic acid were used as the only PPIX-lowering treatment. At 2 years post OLT, he remains well with normal LFTs and no evidence of recurrent EPP liver disease with a mean Erc-PPIX of 73 $\mu\text{mol/L}$ (4101 $\mu\text{g/dL}$).

DISCUSSION

EPP-related progressive liver disease is rare. Therefore, there is much variation in management across centres as demonstrated in our case series.

We present five cases with EPP progressive liver disease and focus on lessons learned in each case combined with a literature review to recommend some strategies to help better manage this unique group of patients.

As up to 5% of patients with EPP develop progressive irreversible liver disease, it is important to be able to identify patients with early liver disease at risk of progression so they can be closely monitored and hepatoprotective therapy initiated. Whilst there are no predictors for the development of progressive liver disease, mild LFT derangement, with values up to three-fold the upper limit of normal, is an abnormality suggestive of liver involvement with greater elevation correlating with more severe liver injury. (13-15) However, LFTs may be normal in patients with EPP-related fibrosis and cholestasis. (13, 15-17) Since PPIX excretion decreases with progressive liver injury with a consequent rise in Erc-PPIX, measuring Erc-PPIX may identify patients with early liver involvement at risk of progression. A 20-year study on hepatobiliary complications of EPP found that those with EPP liver disease had higher Erc-PPIX levels than those without liver involvement ($38 \pm 8 \mu\text{mol/L}$ vs $12 \pm 3 \mu\text{mol/L}$) or ($1573 \pm 449 \mu\text{g/dL}$ vs $674 \pm 169 \mu\text{g/dL}$), and that Erc-PPIX levels of $>20 \mu\text{mol/L}$ ($1124 \mu\text{g/dL}$) were associated with severe intrahepatic cholestasis and levels $>27 \mu\text{mol/L}$ ($1517 \mu\text{g/dL}$) were associated with cirrhosis.(5) An increase in urinary coproporphyrin excretion to $>0.2 \mu\text{mol/24 hours}$ (normal $<0.1 \mu\text{mol/24 hours}$) and an isomer I/III ratio of up to 40-80% (normal $<31\%$) has also been considered sensitive and specific for liver involvement and cholestasis.(5) In our cohort, one patient (case 3) had developed transient transaminitis at childhood and another (case 4) had normal LFTs, but an Erc-PPIX of $64 \mu\text{mol/L}$ ($3596 \mu\text{g/dL}$) two years prior. In the absence of any published guidelines on monitoring patients with EPP for liver involvement, we recommend routine LFTs, Erc-PPIX and 24-hour urine for coproporphyrin excretion and isomer I/III ratio annually or when photosensitivity worsens in all patients with EPP and to proceed to a liver biopsy when there is any degree of LFT derangement, an Erc-PPIX level of $>20 \mu\text{mol/L}$ ($1124 \mu\text{g/dL}$) or an increase of urinary coproporphyrin to $>0.2 \mu\text{mol/24 hours}$ with an isomer I/III ratio of $>40\%$. In those whose Erc-PPIX and urinary coproporphyrin levels are above the aforementioned values and in

those with deranged LFTs and evidence of PPIX-associated portal intrahepatic cholestasis or fibrosis in the liver biopsy, we recommend PPIX-lowering treatment and close monitoring. (Figure 4)

There are limited data on the efficacy of PPIX-lowering treatment in halting or slowing the progression of EPP liver disease. Oral medications which increase PPIX excretion, such as cholestyramine and ursodeoxycholic acid, have been utilised. There are three case reports supporting the efficacy of cholestyramine at a dose of 12 g daily in normalizing LFTs in those with early liver disease and, in two of the reports, reducing Erc-PPIX levels and improving liver fibrosis a year after therapy. (18-20) Similarly, two case reports supported the efficacy of 15 mg/kg/d of ursodeoxycholic acid in improving LFTs and slowing fibrosis progression. (13, 21) In our cohort, cases 1 and 2 were diagnosed with hepatic EPP with periportal and bridging fibrosis respectively but only the latter was started on cholestyramine. We recommend using both cholestyramine, 12g daily, and ursodeoxycholic 10-15mg/kg/d as PPIX-lowering treatment in patients with early EPP liver disease, with close monitoring of LFTs and Erc-PPIX, aiming to normalise LFTs and to reduce Erc-PPIX to <20 $\mu\text{mol/L}$ (1124 $\mu\text{g/dL}$). We recommend escalating treatment to parenteral PPIX-lowering treatment if this strategy fails. (Figure 4)

In patients presenting with progressive liver disease, manifesting with cirrhosis, and/or recurrent EPP crisis, ursodeoxycholic acid and cholestyramine should be started, but parenteral therapy to rapidly and profoundly reduce PPIX levels is needed along with referral for OLT and AlloSCT. This can prevent further liver damage and is essential in preventing perioperative complications of transplantation and early post-OLT EPP recurrence. (5, 8, 22, 23) Parenteral therapy includes measures to inhibit PPIX production such as heme (hematin) infusion, RBC transfusion and/or RBC hyper transfusion combined with measures to remove circulating PPIX with red cell exchange or plasma exchange. There is no consensus on when plasma exchange should be used over red cell exchange. Since hepatic uptake of PPIX is mainly from the plasma compartment, plasma exchange

offers the most rapid reduction of plasma protoporphyrin (P-PPIX) accessible by the liver and would be theoretically ideal for EPP crises. Conversely, red cell exchange causes a more substantial reduction in total PPIX, reducing both Erc-PPIX and P-PPIX, making it theoretically more effective at durably lowering and maintaining lower total PPIX levels.(24) The literature suggests that the frequency at which combination therapy is administered is as important as the treatment type.(25, 26) A recurring reported phenomenon, also observed in cases 1 and 4, is the rapid rebound rise in PPIX levels associated with episodes of crisis, axonal neuropathy and rapid deterioration of liver disease when the frequency of parenteral treatment is reduced following clinical and biochemical improvement. This can be fatal despite reinstituting PPIX-lowering measures. (22, 25) Hence, aiming for a target Erc-PPIX and adjusting the frequency of combination therapy accordingly may be a rational approach. There is currently no accepted target Erc-PPIX level to aim for, but maintaining Erc-PPIX level below the 20 $\mu\text{mol/L}$ (1124 $\mu\text{g/dL}$)-cut-off associated with liver involvement-seems reasonable but may prove difficult to achieve in established cirrhosis due to impaired PPIX excretion. Crises have been reported to occur with Erc-PPIX levels of $\geq 82\mu\text{mol/L}$ (4607 $\mu\text{g/dL}$). (8) and neuropathy has been reported to occur with levels as low as 41 $\mu\text{mol/L}$ (2304 $\mu\text{g/dL}$),(27) although the majority of cases have been reported with higher levels.(9) Therefore, we recommend reducing Erc-PPIX levels in those with progressive liver disease to $< 40 \mu\text{mol/L}$ (2247 $\mu\text{g/dL}$), preferably to $<20 \mu\text{mol/L}$ (1124 $\mu\text{g/dL}$), and to regularly monitor Erc-PPIX levels on a weekly basis allowing early adjustment of parenteral treatment to a frequency which maintains these levels. (Figure 4)

Iron deficiency and IDA are common in patients with EPP.(28, 29) In patients with X-linked protoporphyria(XLP) with iron deficiency, there is sufficient evidence that iron repletion improves photosensitivity, reduces Erc-PPIX and even liver damage;(29, 30) We therefore, recommend that all patients with XLP should have iron studies done regularly to ensure iron stores remain replete. In EPP secondary to FECH deficiency with concomitant iron deficiency, the benefits of iron supplementation are less. In a few case

reports, it reduces PPIX and photosensitivity. (13, 31) However, in most published reports, iron supplementation has been associated with increasing PPIX levels, worsening photosensitivity and liver function. (29, 31, 32) Iron deficiency may in fact be protective in these patients, as aminolevulinic acid synthase 2 (ALAS2) expression is positively regulated by iron.(28), The increased ALAS2 function following iron administration explains the increase in PPIX levels. In our fifth case, iron infusion, given for a serum ferritin of 11 µg/L and a Hb of 119g/L was associated with a rapid deterioration of liver function, expediting OLT. We therefore think it prudent to follow the suggestion that iron supplementation in EPP due to FECH deficiency should be reserved to those with symptomatic IDA with Hb of <100 g/L at small doses with close monitoring of PPIX.(30)

Post liver transplantation, recurrent EPP liver disease has been reported in 65%-80% of patients.(8, 9, 26) There are limited published data on which PPIX-lowering treatment can effectively prevent or delay recurrent liver disease. Cholestyramine and ursodeoxycholic acid have been used with variable success. (6, 26) In our cohort, early recurrent EPP liver disease was diagnosed in two of three patients despite ursodeoxycholic acid in both and cholestyramine in one. Recurrent EPP liver disease usually requires parenteral PPIX-lowering treatment. RBC hypertransfusion, hematin infusion and plasmapheresis have been used with variable success. (8, 33), Red cell exchange has been successfully used but its long-term use is associated with risk of iron overload. (26) In our cohort, red cell exchange was successfully used for recurrence in two cases (3 and 4). Iron overload occurred in one of these and potentially contributed to the progression of liver disease as evident by the high serum ferritin and high grade siderosis that can't be explained by EPP or cirrhosis in the absence of iron overload. (34, 35) Hemosiderosis post long-term red cell exchange is reported(36) despite adjustments to achieve minimal iron loading by modulating the post-exchange haematocrit; when performed monthly, there is still a net iron load of 0.05mg/kg/day (37), that needs at least 20mg/kg/day of deferasirox to prevent iron overload.(36) , Factors predisposing to iron overload in our case include third weekly exchange, concomitant oral iron supplementation, inability to tolerate

adequate doses of deferasirox and possibly C282Y HFE gene heterozygosity state. Of note, even before cirrhosis was diagnosed, frequent red cell exchange was only able to achieve Erc-PPIX levels of 60-80 $\mu\text{mol/L}$ (3371-4494 $\mu\text{g/dL}$); it is conceivable that increased iron load was part of a vicious cycle by increasing expression of ALAS2, increasing the PPIX and leading to the need for more frequent red cell exchange. Since recurrent EPP liver disease is the rule, and PPIX-lowering treatments are invasive with variable efficacy with potential complications, AlloSCT early after OLT, to cure the defect in heme synthesis should be the goal. (9, 26, 38) Until AlloSCT is carried out, some form of PPIX-lowering treatment is needed, with treatment choice, dose and frequency adjusted to achieved low Erc-PPIX. We suggest aiming for levels $<20\mu\text{mol/L}$ (1124 $\mu\text{g/dL}$), as higher levels are associated with intrahepatic cholestasis and progressive liver disease in native livers, if regular red cell exchange is needed, serum ferritin levels should be monitored and, if rising, oral iron chelation should be considered. (Figure 4)

The results of only a handful of AlloSCT for EPP have been published, 2 in the pediatric population and 2 in the adult population (2, 38-41). In the pediatric literature, there are two reported cases of sequential OLT and AlloSCT. The first, from an HLA-matched sister, resulted in graft rejection but using a more aggressive myeloablative conditioning regimen in the second attempt resulted in successful engraftment.(2) The latter achieved engraftment using a myeloablative conditioning regimen but was complicated with delayed immune recovery and fatal disseminated varicella zoster attributed to T-cell depletion.(38)

In the adult population, two cases have been described in detail, both from matched-unrelated donors. The first was complicated with graft failure overcome in the second attempt with more aggressive myeloablation. (41) The second, which was a sequential OLT and AlloSCT, was successful using a reduced-intensity conditioning regimen consisting of fludarabine, busulfan and total body irradiation without T cell depletion.(40) In our cases, both allograft attempts resulted in initial graft failure which was overcome successfully in one by more aggressive conditioning with melphalan and

omission of T cell depletion; in the other the addition of fludarabine was unsuccessful. These observations are consistent with the emerging experience in AlloSCT for chemotherapy naïve patients with non-malignant disease which suggests that aggressive myelo-lymphoablative conditioning may be needed to facilitate donor engraftment. Limited experience in EPP patients suggest that, as in some allograft series for leukaemia, profound depletion of donor T cells may increase the risk of engraftment failure.(11, 12)

In conclusion, our observations and literature review suggest that patients with EPP with Erc-PPIX levels $>20 \mu\text{mol/L}$ ($>1124 \mu\text{g/dL}$), increase in urinary coproporphyrin excretion and/or with deranged LFTS should undergo a liver biopsy and considered for oral PPIX-lowering medications as cholestyramine and ursodeoxycholic acid with an aim to normalise LFTS and reduce Erc-PPIX to less than $20 \mu\text{mol/L}$ ($1124 \mu\text{g/dL}$). Iron deficiency should be treated in all XLP patients, but only used in EPP FECH deficient patients if it causes severe anaemia. Those with more serious liver disease, should have parenteral PPIX-lowering therapy and be considered for sequential OLT and AlloSCT. Following aggressive PPIX-lowering, ongoing maintenance therapy is required to maintain low levels of Erc-PPIX and prevent recurrence post-OLT. Regular red cell exchange appears to be effective in maintaining low PPIX levels but may result in iron overload without other interventions such as iron chelation. The definitive cure remains an AlloSCT.

SUMMARY

As up to 5% of patients with EPP develop progressive irreversible liver disease, it is critical to have a clinical strategy for managing this unique group of patients. The EPP management algorithm presented in figure 4 offers a practical approach to the management of EPP related liver disease. Cutaneous manifestations of EPP, characterised by immediate painful photosensitivity occurring in infancy or early childhood, always precedes hepatic manifestations. (42) The biochemical diagnosis of EPP is established by the detection of significantly elevated total Erc-PPIX levels. It is important to differentiate EPP secondary to FECH deficiency from XLP as their management differs in several aspects. EPP secondary to FECH deficiency is

suggested by decreased FECH levels to < 50% of normal and metal-free protoporphyrin accounting for (85%–100%) total Erc-PPIX, and confirmed by identification of biallelic mutations by sequencing the FECH gene.(43, 44) X-Linked protoporphyria is suggested by normal FECH levels and a lower fraction of metal-free protoporphyrin (50%–85% of the total Erc-PPIX), and confirmed by ALAS2 sequencing. (45, 46) All patients with EPP should be assessed for overt liver involvement. In those with no overt liver involvement, LFTs, Erc-PPIX and 24-hour urine for coproporphyrin excretion and isomer I/III ratio should be done annually or whenever photosensitivity worsens. When Erc-PPIX levels >20 µmol/L, there is an increase in urinary coproporphyrin excretion and/or LFTS become deranged, a liver biopsy is needed and patients should be considered for oral PPIX-lowering medications as cholestyramine and ursodeoxycholic acid with an aim to normalize LFTS and reduce Erc-PPIX to less than 20 µmol/L (1124 µg/dL). Iron deficiency should be treated in all XLP patients, but only used in EPP FECH deficient patients if it causes severe anemia. Features of overt liver involvement are not specific and include mild to moderate liver enzymes elevation, jaundice, recurrent episodes of EPP crisis, cirrhosis and end stage liver disease. Other common liver diseases need to be ruled out with the appropriate blood tests and imaging modalities. A liver biopsy is essential to confirm EPP related liver disease and to stage fibrosis. Those with early EPP liver disease should initially be managed with oral PPIX-lowering treatment as detailed above. Patients failing oral PPIX-lowering treatment and patients with more serious liver disease should have parenteral PPIX-lowering therapy and be considered for sequential OLT and AlloSCT. Following aggressive PPIX-lowering, ongoing maintenance therapy is required and adjusted to maintain low levels of Erc-PPIX aiming for a target of <40 µmol/L (2248 µg/dL) or preferably of <20 µmol/L (1124 µg/dL). Post-OLT, PPIX-lowering treatment should be resumed aiming for a target Erc-PPIX of <20 µmol/L (1124 µg/dL). Regular red cell exchange appears to be effective in maintaining low PPIX levels but may result in iron overload without other interventions such as iron chelation. The definitive cure remains an AlloSCT. Myelo-lymphoablative conditioning and omitting T-cell depletion may be needed to facilitate donor engraftment.

1. Lecha M, Puy H, Deybach JC. Erythropoietic protoporphyria. *Orphanet journal of rare diseases*. 2009;4:19.
2. Rand EB, Bunin N, Cochran W, Ruchelli E, Olthoff KM, Bloomer JR. Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. *Pediatrics*. 2006;118(6):e1896-9.
3. Went LN, Klasen EC. Genetic aspects of erythropoietic protoporphyria. *Annals of human genetics*. 1984;48(Pt 2):105-17.
4. Anstey AV, Hift RJ. Liver disease in erythropoietic protoporphyria: insights and implications for management. *Gut*. 2007;56(7):1009-18.
5. Doss MO, Frank M. Hepatobiliary implications and complications in protoporphyria, a 20-year study. *Clin Biochem*. 1989;22(3):223-9.
6. Gross U, Frank M, Doss MO. Hepatic complications of erythropoietic protoporphyria. *Photodermatol Photoimmunol Photomed*. 1998;14(2):52-7.
7. Rank JM, Carithers R, Bloomer J. Evidence for neurological dysfunction in end-stage protoporphyric liver disease. *Hepatology (Baltimore, Md)*. 1993;18(6):1404-9.
8. McGuire BM, Bonkovsky HL, Carithers RL, Jr., Chung RT, Goldstein LI, Lake JR, et al. Liver transplantation for erythropoietic protoporphyria liver disease. *Liver Transpl*. 2005;11(12):1590-6.
9. Wahlin S, Stal P, Adam R, Karam V, Porte R, Seehofer D, et al. Liver transplantation for erythropoietic protoporphyria in Europe. *Liver Transpl*. 2011;17(9):1021-6.
10. Rerknimitr R, Sherman S, Fogel EL, Kalayci C, Lumeng L, Chalasani N, et al. Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. *Gastrointestinal endoscopy*. 2002;55(2):224-31.
11. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. *Blood*. 2001;98(12):3192-204.
12. Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. *Bone Marrow Transplant*. 2013;48(4):537-43.

13. Rademakers LH, Cleton MI, Kooijman C, Baart de la Faille H, van Hattum J. Early involvement of hepatic parenchymal cells in erythrohepatic protoporphyria? An ultrastructural study of patients with and without overt liver disease and the effect of chenodeoxycholic acid treatment. *Hepatology*. 1990;11(3):449-57.
14. Eales L. Liver involvement in erythropoietic protoporphyria (EP). *Int J Biochem*. 1980;12(5-6):915-23.
15. Bloomer JR, Phillips MJ, Davidson DL, Klatskin G. Hepatic disease in erythropoietic protoporphyria. *The American Journal of Medicine*. 1975;58(6):869-82.
16. Cripps DJ, Goldfarb SS. Erythropoietic protoporphyria: hepatic cirrhosis. *Br J Dermatol*. 1978;98(3):349-54.
17. Mooyaart BR, de Jong GMT, van der Veen S, Driessen LHHM, Beukeveld GJJ, Grond J, et al. Hepatic Disease in Erythropoietic Protoporphyria. *Dermatology*. 1986;173(3):120-30.
18. Bloomer JR. Pathogenesis and therapy of liver disease in protoporphyria. *Yale J Biol Med*. 1979;52(1):39-48.
19. McCullough AJ, Barron D, Mullen KD, Petrelli M, Park MC, Mukhtar H, et al. Fecal protoporphyrin excretion in erythropoietic protoporphyria: effect of cholestyramine and bile acid feeding. *Gastroenterology*. 1988;94(1):177-81.
20. Yoo DJ, Lee HC, Yu E, Jin YJ, Shim JH, Kim KM, et al. Cholestyramine resin for erythropoietic protoporphyria with severe hepatic disease: a case report. *Korean J Hepatol*. 2010;16(1):83-8.
21. Pirlich M, Lochs H, Schmidt HH. Liver cirrhosis in erythropoietic protoporphyria: improvement of liver function with ursodeoxycholic acid. *Am J Gastroenterol*. 2001;96(12):3468-9.
22. Reichheld JH, Katz E, Banner BF, Szymanski IO, Saltzman JR, Bonkovsky HL. The value of intravenous heme-albumin and plasmapheresis in reducing postoperative complications of orthotopic liver transplantation for erythropoietic protoporphyria. *Transplantation*. 1999;67(6):922-8.
23. Do KD, Banner BF, Katz E, Szymanski IO, Bonkovsky HL. Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after orthotopic liver transplantation. *Transplantation*. 2002;73(3):469-72.
24. Wahlin S, Harper P. Pretransplant albumin dialysis in erythropoietic protoporphyria: a costly detour. *Liver Transpl*. 2007;13(11):1614-5.

25. Pagano MB, Hobbs W, Linenberger M, Delaney M. Plasma and red cell exchange transfusions for erythropoietic protoporphyria: a case report and review of the literature. *J Clin Apher.* 2012;27(6):336-41.
26. Dowman JK, Gunson BK, Mirza DF, Badminton MN, Newsome PN. UK experience of liver transplantation for erythropoietic protoporphyria. *J Inherit Metab Dis.* 2011;34(2):539-45.
27. Muley SA, Midani HA, Rank JM, Carithers R, Parry GJ. Neuropathy in erythropoietic protoporphyrias. *Neurology.* 1998;51(1):262-5.
28. Barman-Aksoezen J, Girelli D, Aurizi C, Schneider-Yin X, Campostrini N, Barbieri L, et al. Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity. *J Inherit Metab Dis.* 2017;40(3):433-41.
29. Whatley SD, Ducamp S, Gouya L, Grandchamp B, Beaumont C, Badminton MN, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. *Am J Hum Genet.* 2008;83(3):408-14.
30. Jasmin Barman-Aksoezen XS-Y, Elisabeth I. Minder. Iron in erythropoietic protoporphyrias: Dr. Jekyll or Mr. Hyde? *Journal of Rare Diseases Research & Treatment.* 2017;2(4):1-5.
31. Mercurio MG, Prince G, Weber FL, Jr., Jacobs G, Zaim MT, Bickers DR. Terminal hepatic failure in erythropoietic protoporphyria. *J Am Acad Dermatol.* 1993;29(5 Pt 2):829-33.
32. Milligan A, Graham-Brown RA, Sarkany I, Baker H. Erythropoietic protoporphyria exacerbated by oral iron therapy. *Br J Dermatol.* 1988;119(1):63-6.
33. Dellon ES, Szczepiorkowski ZM, Dzik WH, Graeme-Cook F, Ades A, Bloomer JR, et al. Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoietic protoporphyria. *Transplantation.* 2002;73(6):911-5.
34. Intragumtornchai T, Rojnukkarin P, Swasdikul D, Israsena S. The role of serum ferritin in the diagnosis of iron deficiency anaemia in patients with liver cirrhosis. *J Intern Med.* 1998;243(3):233-41.
35. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. *N Engl J Med.* 1974;290(22):1213-6.
36. Fasano RM, Leong T, Kaushal M, Sagiv E, Luban NL, Meier ER. Effectiveness of red blood cell exchange, partial manual exchange, and simple transfusion concurrently with iron chelation therapy in reducing iron overload in chronically transfused sickle cell anemia patients. *Transfusion.* 2016;56(7):1707-15.

37. Kim HC, Dugan NP, Silber JH, Martin MB, Schwartz E, Ohene-Frempong K, et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. *Blood*. 1994;83(4):1136-42.
38. Smiers FJ, Van de Vijver E, Delsing BJ, Lankester AC, Ball LM, Rings EH, et al. Delayed immune recovery following sequential orthotopic liver transplantation and haploidentical stem cell transplantation in erythropoietic protoporphyria. *Pediatr Transplant*. 2010;14(4):471-5.
39. Wahlin S, Harper P. The role for BMT in erythropoietic protoporphyria. *Bone Marrow Transplant*. 2010;45(2):393-4.
40. Windon AL, Tondon R, Singh N, Abu-Gazala S, Porter DL, Russell JE, et al. Erythropoietic protoporphyria in an adult with sequential liver and hematopoietic stem cell transplantation: A case report. *Am J Transplant*. 2018;18(3):745-9.
41. Wahlin S, Aschan J, Bjornstedt M, Broome U, Harper P. Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. *J Hepatol*. 2007;46(1):174-9.
42. Thunell S, Harper P, Brun A. Porphyrins, porphyrin metabolism and porphyrias. IV. Pathophysiology of erythropoietic protoporphyria--diagnosis, care and monitoring of the patient. *Scand J Clin Lab Invest*. 2000;60(7):581-604.
43. Holme SA, Anstey AV, Finlay AY, Elder GH, Badminton MN. Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life. *Br J Dermatol*. 2006;155(3):574-81.
44. Balwani M. Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management. *Mol Genet Metab*. 2019.
45. Gou EW, Balwani M, Bissell DM, Bloomer JR, Bonkovsky HL, Desnick RJ, et al. Pitfalls in Erythrocyte Protoporphyrin Measurement for Diagnosis and Monitoring of Protoporphyrias. *Clin Chem*. 2015;61(12):1453-6.
46. Balwani M, Doheny D, Bishop DF, Nazarenko I, Yasuda M, Dailey HA, et al. Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. *Mol Med*. 2013;19:26-35.

Table 1: Protoporphyrin IX (PPIX) -Lowering Therapies	
Mechanism	Example
Increasing PPIX* excretion	Ursodeoxycholic acid Cholestyramine
Suppressing erythropoiesis and PPIX production	Iron Hematin or heme arginate infusions Red cell hypertransfusion (target Hb >120g/l)
Removing circulating PPIX	Plasmapheresis Plasma exchange Red cell exchange
PPIX: Protoporphyrin IX Hb: Hemoglobin	

	Age at EPP liver disease (years)	Genetic testing	Available Erc-PPIX levels Y/N (value)	PPIX-lowering treatment before cirrhosis or EPP crisis Y/N (medication)	Age at EPP crisis or cirrhosis	Erc-PPIX $\mu\text{mol/L}$ ($\mu\text{g/dL}$) at EPP crisis or Cirrhosis	Serum Ferritin ($\mu\text{g/L}$) at EPP crisis or cirrhosis	Age at OLT referral	Pre-OLT PPIX-lowering treatment	OLT Y/N (cause if no OLT)
Case 1	38	NA	N	N	41	149 (8371 $\mu\text{g/dL}$)	57	41	Ursodeoxycholic acid Heme arginate RBC hypertransfusion Plasma exchange	N (Died from ESLD and sensorimotor neuropathy on the OLT list)
Case 2	18	NA	N	Y Cholestyramine	20	172 (9663 $\mu\text{g/dL}$)	NA	20	Heme arginate plasmapheresis	N (Died from ESLD and HRS-1 ⁺ while on the waiting list)
Case 3 (XLP)	1.5*	XLP mutation (exon 11)	N	N	15	180 (10112 $\mu\text{g/dL}$)	13	15 And 25**	A) Initial referral Ursodeoxycholic acid Oral iron B) Second referral Plasmapheresis, IV hematin, IV iron and oral iron	Y
Case 4	19	NA	Y (65 $\mu\text{mol/L}$)	N	21	157 (8820 $\mu\text{g/dL}$)	14	21	Ursodeoxycholic acid Cholestyramine Heme arginate RBC hypertransfusion	Y

									Plasma exchange	
Case 5	52	Heterozygous c.616+1G>T c.617-3C>T variants in the FECH gene	N	N	52	210 [#] (11798 µg/dL)	11	64	None	Y
<p>+ HRS: Hepatorenal syndrome</p> <p>*Transient transaminitis noticed at 1.5 years. No regular Liver function tests from then till EPP crisis and cirrhosis.</p> <p>** Initial referral at the age of 15, but liver transplantation was refused by the patient. Second referral at the age of 25</p> <p># This Erc-PPIX level is at the time of ESLD and not the diagnosis of cirrhosis 12 years prior.</p> <p>Reference ranges: Erc-PPIX <1.8 µmol/L. Serum ferritin 20-150 µg/L.</p>										

Author Manuscript

Table 3. A summary of the three cases that had successful orthotopic liver transplantation (OLT)												
	Post OLT preventative PPIX-lowering treatment Y/N (medications)	Recurrent EPP liver disease Y/N (Days post OLT)	Erc-PPIX ($\mu\text{mol/L}$) at recurrence	Effective PPIX- lowering treatment	Mean Erc-PPIX $\mu\text{mol/L}$ ($\mu\text{g/dL}$)	Mean serum ferritin $\mu\text{g/L}$	Iron chelating agent Y/N (Medication and dose)	Second OLT	AlloSCT Y/N (No.)	Type of AlloSCT	Successful grafting	Need for PPIX lowering treatment Y/N (medication)
Case 3	Ursodeoxycholic acid Cholestyramine	Y(20)	55	RCE+	5 (280 $\mu\text{g/dL}$)	312	N	N	Y (2)	1-MUD BMSCT* 2-MUD PBSCT **	1-N (graft loss day 28 2-N (Failed to graft)	Y (Cholestyramine, ursodeoxycholic acid and RCE 4-5 weekly)
Case 4	Ursodeoxycholic acid Ferrous sulphate Plasma exchange day 3	Y(39)	118	RCE	63 (3539 $\mu\text{g/dL}$)	2174	Y (Deferasirox) #	N	Y (2)	1-MUD PBSCT 2-MUD PBSCT **	1-N (graft loss day100) 2-Y (100% donor chimerism day 20	N
Case 5	Ursodeoxycholic acid Cholestyramine Plasma exchange day 1	N			73 (4101 $\mu\text{g/dL}$)	NA	N	N	N	NA		Y (Cholestyramine ursodeoxycholic acid)

	and 3											
<p>+ RCE: Red cell exchange</p> <p>* MUD BMSCT: Matched unrelated donor bone marrow stem cell transplant</p> <p>**MUD PBSCT: Matched unrelated donor peripheral blood stem cell transplant</p> <p># Deferasirox: A dose of 7.5 mg/kg/d tolerated only for 3 weeks. After cirrhosis and grade 4 siderosis was diagnosed with a mean serum ferritin of 2174 µg/L. Deferasirox 250 mg daily was commenced and tolerated.</p>

lt_25632_f1.eps

lt_25632_f2.eps

lt_25632_f3.eps

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Ardalan, ZS;Chandran, S;Vasudevan, A;Angus, PW;Grigg, A;He, S;Macdonald, GA;Strasser, SI;Tate, CJ;Kennedy, GA;Testro, AG;Gow, PJ

Title:

Management of Patients With Erythropoietic Protoporphyria-Related Progressive Liver Disease

Date:

2019-09-30

Citation:

Ardalan, Z. S., Chandran, S., Vasudevan, A., Angus, P. W., Grigg, A., He, S., Macdonald, G. A., Strasser, S. I., Tate, C. J., Kennedy, G. A., Testro, A. G. & Gow, P. J. (2019). Management of Patients With Erythropoietic Protoporphyria-Related Progressive Liver Disease. LIVER TRANSPLANTATION, 25 (11), pp.1620-1633. <https://doi.org/10.1002/lt.25632>.

Persistent Link:

<http://hdl.handle.net/11343/286448>